4/1
08:08 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its price target raised by analysts at HC Wainwright from $4.00 to $7.50. They now have a "buy" rating on the stock.
Medium
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its price target raised by analysts at HC Wainwright from $4.00 to $7.50. They now have a "buy" rating on the stock.
4/1
07:12 am
uncy
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
High
Report
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]
4/1
07:00 am
uncy
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
High
Report
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
3/31
07:00 am
uncy
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
Medium
Report
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
3/26
08:13 pm
uncy
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play [Yahoo! Finance]
Low
Report
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play [Yahoo! Finance]
3/13
08:23 am
uncy
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia [Yahoo! Finance]
Low
Report
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia [Yahoo! Finance]
3/13
07:00 am
uncy
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
Low
Report
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
2/20
07:00 am
uncy
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
Low
Report
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
1/29
08:18 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Low
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
1/28
07:00 am
uncy
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
Medium
Report
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
1/8
08:00 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Medium
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
1/7
07:00 am
uncy
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
Low
Report
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science